Maksakirroosi, näytönastekatsausten kirjallisuusviitteet

Kirjallisuutta

1. Agarwal A, Taneja S, Chopra M, ym. Animal Naming Test - a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy. Clin Exp Hepatol 2020;6(2):116-124 «PMID: 32728628»PubMed
2. Alla M, Shasthry SM, Varshney M ym. Naltrexone is safe and effective in achieving abstinence and reducing alcohol craving in cirrhotic patients: a double blind randomized placebo controlled trial. Journal of hepatology 2023;78:7-8
3. Are VS, Vuppalanchi R, Vilar-Gomez E, ym. Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. Clin Gastroenterol Hepatol 2021;19(6):1292-1293.e3 «PMID: 32629127»PubMed
4. Campagna F, Montagnese S, Ridola L, ym. The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology 2017;66(1):198-208 «PMID: 28271528»PubMed
5. Canivet CM, Costentin C, Irvine KM, ym. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology 2023;77(3):920-930 «PMID: 35822302»PubMed
6. Combes B, Emerson SS, Flye NL, ym. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005;42(5):1184-93 «PMID: 16250039»PubMed
7. Connoley D, Patel PJ, Hogan B, ym. The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. BMC Gastroenterol 2021;21(1):268 «PMID: 34182924»PubMed
8. Cusi K, Isaacs S, Barb D, ym. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28(5):528-562 «PMID: 35569886»PubMed
9. Day J, Patel P, Parkes J, ym. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. J Appl Lab Med 2019;3(5):815-826 «PMID: 31639756»PubMed
10. de Vries EMG, Färkkilä M, Milkiewicz P, ym. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int 2017;37(10):1554-1561 «PMID: 28267887»PubMed
11. Dunn W, Talaat N, Haglund J ym. The availability of the enhanced liver fibrosis (elf) test increases the rate of diagnosis of advanced fibrosis and cirrhosis during evaluation for fatty liver disease. Hepatology (Baltimore, Md) 2021;74(SUPPL 1):988A-9A
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75(3):659-689 «PMID: 34166721»PubMed
13. Ginès P, Castera L, Lammert F, ym. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology 2022;75(1):219-228 «PMID: 34537988»PubMed
14. Gratacós-Ginès J, Bruguera P, Pérez-Guasch M, ym. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis. Hepatology 2024;79(2):368-379 «PMID: 37625154»PubMed
15. Hinkson A, Lally H, Gibson H, ym. Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther 2023;57(7):750-762 «PMID: 36650720»PubMed
16. Huang CH, Yu TY, Tseng WJ, ym. Animal naming test is a simple and valid tool for detecting covert hepatic encephalopathy and predicting outcomes in Chinese-speaking regions: a preliminary study. Ann Med 2023;55(1):2236013 «PMID: 37494454»PubMed
17. Kim BK, Kim HS, Yoo EJ, ym. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 2014;60(6):1911-9 «PMID: 25142433»PubMed
18. Kjaergaard M, Lindvig KP, Thorhauge KH, ym. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol 2023;79(2):277-286 «PMID: 37088311»PubMed
19. Labenz C, Beul L, Toenges G, ym. Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. Eur J Intern Med 2019;60():96-100 «PMID: 30131209»PubMed
20. Liang LY, Wong VW, Tse YK, ym. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2019;49(12):1509-1517 «PMID: 31025388»PubMed
21. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology 2022;163(3):764-774.e1 «PMID: 35842345»PubMed
22. McPherson S, Armstrong MJ, Cobbold JF, ym. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol 2022;7(8):755-769 «PMID: 35490698»PubMed
23. Newsome PN, Cramb R, Davison SM, ym. Guidelines on the management of abnormal liver blood tests. Gut 2018;67(1):6-19 «PMID: 29122851»PubMed
24. Parkes J, Roderick P, Harris S, ym. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59(9):1245-51 «PMID: 20675693»PubMed
25. Qu Y, Li T, Lin C, ym. Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations. Clin Res Hepatol Gastroenterol 2021;45(5):101729 «PMID: 34091081»PubMed
26. Rasmussen DN, Thiele M, Johansen S, ym. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol 2021;75(5):1017-1025 «PMID: 34118335»PubMed
27. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, ym. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77(5):1797-1835 «PMID: 36727674»PubMed
28. Rosato V, Abenavoli L, Federico A ym. Pharmacotherapy of alcoholic liver disease in clinical practice [Review]. International Journal of Clinical Practice 2016;70(2):119-31
29. Rosman AS, Waraich A, Baraona E, ym. Disulfiram treatment increases plasma and red blood cell acetaldehyde in abstinent alcoholics. Alcohol Clin Exp Res 2000;24(7):958-64 «PMID: 10923997»PubMed
30. Saarinen K, Färkkilä M, Jula A, ym. Enhanced liver Fibrosis® test predicts liver-related outcomes in the general population. JHEP Rep 2023;5(7):100765 «PMID: 37333973»PubMed
31. Sanyal AJ, Harrison SA, Ratziu V, ym. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology 2019;70(6):1913-1927 «PMID: 30993748»PubMed
32. Sharma C, Cococcia S, Ellis N, ym. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol 2021;36(7):1788-1802 «PMID: 33668077»PubMed
33. Simbrunner B, Marculescu R, Scheiner B, ym. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int 2020;40(7):1713-1724 «PMID: 32358998»PubMed
34. Singal AG, Zhang E, Narasimman M, ym. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol 2022;77(1):128-139 «PMID: 35139400»PubMed
35. Srivastava A, Gailer R, Tanwar S, ym. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol 2019;71(2):371-378 «PMID: 30965069»PubMed
36. Srivastava A, Jong S, Gola A, ym. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19(1):122 «PMID: 31296161»PubMed
37. Thiele M, Madsen BS, Hansen JF, ym. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology 2018;154(5):1369-1379 «PMID: 29317276»PubMed
38. Tzartzeva K, Obi J, Rich NE, ym. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018;154(6):1706-1718.e1 «PMID: 29425931»PubMed
39. Vali Y, Lee J, Boursier J, ym. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2020;73(2):252-262 «PMID: 32275982»PubMed
40. Varshney M, Shasthry SM, Sarin SK. Evaluation of safety, tolerability and effectiveness of naltrexone for long-term management of alcohol use disorder in patients with liver cirrhosis. Hepatology (Baltimore, Md) 2020;72 (1 SUPPL):162A
41. Xie Q, Zhou X, Huang P, ym. The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis. PLoS One 2014;9(4):e92772 «PMID: 24736610»PubMed
42. Younossi ZM, Felix S, Jeffers T, ym. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2021;4(9):e2123923 «PMID: 34529067»PubMed
43. Younossi ZM, Noureddin M, Bernstein D, ym. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116(2):254-262 «PMID: 33284184»PubMed